These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 34237090)

  • 1. Clinical and economic impact of universal varicella vaccination in Norway: A modeling study.
    Pawaskar M; Burgess C; Pillsbury M; Wisløff T; Flem E
    PLoS One; 2021; 16(7):e0254080. PubMed ID: 34237090
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness of routine varicella vaccination using the measles, mumps, rubella and varicella vaccine in France: an economic analysis based on a dynamic transmission model for varicella and herpes zoster.
    Littlewood KJ; Ouwens MJ; Sauboin C; Tehard B; Alain S; Denis F
    Clin Ther; 2015 Apr; 37(4):830-841.e7. PubMed ID: 25721380
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Economic Evaluation of Universal Varicella Vaccination in Mexico.
    Chacon-Cruz E; Meroc E; Costa-Clemens SA; Clemens R; Verstraeten T
    Pediatr Infect Dis J; 2022 May; 41(5):439-444. PubMed ID: 34966138
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Health Impact and Cost-effectiveness Assessment for the Introduction of Universal Varicella Vaccination in Switzerland.
    Heininger U; Pillsbury M; Samant S; Lienert F; Guggisberg P; Gani R; O'Brien E; Pawaskar M
    Pediatr Infect Dis J; 2021 Jun; 40(6):e217-e221. PubMed ID: 33872276
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Long-Term Clinical and Economic Impact of Universal Varicella Vaccination in Slovenia.
    Burgess C; Kujawski S; Lapornik A; Bencina G; Pawaskar M
    J Health Econ Outcomes Res; 2022; 9(2):95-102. PubMed ID: 36196453
    [No Abstract]   [Full Text] [Related]  

  • 6. Cost-effectiveness of varicella and herpes zoster vaccination in Sweden: An economic evaluation using a dynamic transmission model.
    Wolff E; Widgren K; Scalia Tomba G; Roth A; Lep T; Andersson S
    PLoS One; 2021; 16(5):e0251644. PubMed ID: 33984060
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost effectiveness and budget impact of universal varicella vaccination in Russia.
    Marijam A; Safonova E; Scherbakov M; Shpeer E; Van Oorschot D; Rudakova A; Tatochenko V; Briko N
    Hum Vaccin Immunother; 2022 Nov; 18(5):2045152. PubMed ID: 35258445
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Distribution of Health Effects and Cost-effectiveness of Varicella Vaccination are Shaped by the Impact on Herpes Zoster.
    van Lier A; Lugnér A; Opstelten W; Jochemsen P; Wallinga J; Schellevis F; Sanders E; de Melker H; van Boven M
    EBioMedicine; 2015 Oct; 2(10):1494-9. PubMed ID: 26629544
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Childhood varicella-zoster virus vaccination in Belgium: cost-effective only in the long run or without exogenous boosting?
    Bilcke J; van Hoek AJ; Beutels P
    Hum Vaccin Immunother; 2013 Apr; 9(4):812-22. PubMed ID: 23321955
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The cost-effectiveness of varicella and combined varicella and herpes zoster vaccination programmes in the United Kingdom.
    van Hoek AJ; Melegaro A; Gay N; Bilcke J; Edmunds WJ
    Vaccine; 2012 Feb; 30(6):1225-34. PubMed ID: 22119592
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Varicella vaccination in England and Wales: cost-utility analysis.
    Brisson M; Edmunds WJ
    Arch Dis Child; 2003 Oct; 88(10):862-9. PubMed ID: 14500303
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Systematic review of models assessing the economic value of routine varicella and herpes zoster vaccination in high-income countries.
    Damm O; Ultsch B; Horn J; Mikolajczyk RT; Greiner W; Wichmann O
    BMC Public Health; 2015 Jun; 15():533. PubMed ID: 26041469
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epidemiological Impact and Cost-Effectiveness of Varicella Vaccination Strategies in the United Kingdom.
    Akpo EIH; Cristeau O; Hunjan M; Casabona G
    Clin Infect Dis; 2021 Dec; 73(11):e3617-e3626. PubMed ID: 33173938
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A combination measles, mumps, rubella, and varicella vaccine (ProQuad) given to 4- to 6-year-old healthy children vaccinated previously with M-M-RII and Varivax.
    Reisinger KS; Brown ML; Xu J; Sullivan BJ; Marshall GS; Nauert B; Matson DO; Silas PE; Schödel F; Gress JO; Kuter BJ;
    Pediatrics; 2006 Feb; 117(2):265-72. PubMed ID: 16452343
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness analysis of universal varicella vaccination in Turkey using a dynamic transmission model.
    Wolfson LJ; Daniels VJ; Pillsbury M; Kurugöl Z; Yardimci C; Kyle J; Dinleyici EC
    PLoS One; 2019; 14(8):e0220921. PubMed ID: 31408505
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modeling the impact of combined vaccination programs against varicella and herpes zoster in Norway.
    Marchetti S; Guzzetta G; Flem E; Mirinaviciute G; Scalia Tomba G; Manfredi P
    Vaccine; 2018 Feb; 36(8):1116-1125. PubMed ID: 29366704
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Review of the United States universal varicella vaccination program: Herpes zoster incidence rates, cost-effectiveness, and vaccine efficacy based primarily on the Antelope Valley Varicella Active Surveillance Project data.
    Goldman GS; King PG
    Vaccine; 2013 Mar; 31(13):1680-94. PubMed ID: 22659447
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of a vaccination programme in children vaccinated with ProQuad, and ProQuad-specific effectiveness against varicella in the Veneto region of Italy.
    Giaquinto C; Gabutti G; Baldo V; Villa M; Tramontan L; Raccanello N; Russo F; Poma C; Scamarcia A; Cantarutti L; Lundin R; Perinetti E; Cornen X; Thomas S; Ballandras C; Souverain A; Hartwig S
    BMC Infect Dis; 2018 Mar; 18(1):103. PubMed ID: 29506477
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The health and economic impact of switching vaccines in universal varicella vaccination programs using a dynamic transmission model: An Israel case study.
    Kujawski SA; Burgess C; Agi O; Attias-Geva Z; Pillsbury M; Greenberg D; Bencina G; Pawaskar M
    Hum Vaccin Immunother; 2022 Nov; 18(6):2124784. PubMed ID: 36315970
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The impact of demographic changes, exogenous boosting and new vaccination policies on varicella and herpes zoster in Italy: a modelling and cost-effectiveness study.
    Melegaro A; Marziano V; Del Fava E; Poletti P; Tirani M; Rizzo C; Merler S
    BMC Med; 2018 Jul; 16(1):117. PubMed ID: 30012132
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.